Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 20/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128909 | 0.95 | TNK2 (1.00) | TNK2 | |
| SCHEMBL4357551 | 0.91 | TNK2 (1.00) | TNK2 | |
| SCHEMBL4357548 | 0.91 | TNK2 (1.00) | TNK2 | |
| SCHEMBL1128598 | 0.91 | TNK2 (1.00) | TNK2 | |
| SCHEMBL13618412 | 0.91 | TNK2 (1.00) | TNK2 | |
| SCHEMBL1128937 | 0.90 | TNK2 (1.00) | TNK2 | |
| SCHEMBL1128717 | 0.90 | TNK2 (1.00) | TNK2 | |
| SCHEMBL22236031 | 0.90 | TNK2 (0.85) | TNK2 | |
| SCHEMBL22236169 | 0.90 | TNK2 (0.85) | TNK2 | |
| SCHEMBL29409812 | 0.90 | TNK2 (0.85) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955505-A | Bruton tyrosine kinase inhibitors | 杭州邦顺制药有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118955506-A | Bruton tyrosine kinase inhibitors | 杭州邦顺制药有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-113365631-B | Bruton tyrosine kinase inhibitors | 杭州邦顺制药有限公司 | 2024-08-30 | — | — | CN | claimed |
| US-20220064162-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | LIAO, XIBIN | 2022-03-03 | — | — | US | claimed |
| EP-3911326-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Hangzhou Bangshun Pharmaceutical Co., Ltd. (CN) | 2021-11-24 | — | — | EP | claimed |
| CN-113365631-A | Bruton's tyrosine kinase inhibitors | 杭州邦顺制药有限公司 | 2021-09-07 | — | — | CN | claimed |
| WO-2020150681-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | LIAO XIBIN (US) | 2020-07-23 | — | — | WO | claimed |
| US-12435079-B2 | Bruton's tyrosine kinase inhibitors | Liao, Xibin (US) | 2025-10-07 | — | — | US | disclosed |
| CN-118955505-A | Bruton tyrosine kinase inhibitors | 杭州邦顺制药有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118955506-A | Bruton tyrosine kinase inhibitors | 杭州邦顺制药有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113365631-B | Bruton tyrosine kinase inhibitors | 杭州邦顺制药有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20220064162-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | LIAO, XIBIN | 2022-03-03 | — | — | US | disclosed |
| EP-3911326-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Hangzhou Bangshun Pharmaceutical Co., Ltd. (CN) | 2021-11-24 | — | — | EP | disclosed |
| CN-113365631-A | Bruton's tyrosine kinase inhibitors | 杭州邦顺制药有限公司 | 2021-09-07 | — | — | CN | disclosed |
| WO-2020150681-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | LIAO XIBIN (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150681-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | LIAO XIBIN (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435079-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | TNK2 230/4885 |
| US-20220064162-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | TNK2 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.